What is Auxilius?
Founded in 2020 and based in New York, Auxilius provides a specialized software platform designed to automate and optimize financial management for clinical trials within the biopharmaceutical industry. The company's solution integrates real-time clinical data, invoices, and team inputs to automate expense accruals, budgeting, forecasting, and financial planning, thereby replacing traditional manual spreadsheet methods. Auxilius aims to enhance forecast accuracy, control trial expenditures, and mitigate financial risks for biotech and pharmaceutical firms. Its platform offers investigator spend intelligence, site payment reconciliation, and built-in controls to support audit readiness and compliance. The software integrates seamlessly with existing clinical trial management systems, EDC tools, and ERP systems, generating necessary financial reports and forecasts. Auxilius complements its technology with a dedicated team of financial and accounting professionals, offering robust customer support.
How much funding has Auxilius raised?
Auxilius has raised a total of $20M across 2 funding rounds:
Series A
$10M
Other Financing Round
$10M
Series A (2022): $10M with participation from Bain Capital Ventures, Renegade Partners, and XYZ Venture Capital
Other Financing Round (2024): $10M led by SignalFire
Key Investors in Auxilius
SignalFire
SignalFire is a venture capital firm that leverages data and AI to support early-stage companies, with a focus on sectors including healthtech and cybersecurity. They provide extensive portfolio support and strategic insights.
Bain Capital Ventures
Bain Capital Ventures is the venture capital arm of Bain Capital, known for its early-stage investments in technology companies. They manage significant capital and actively support a diverse portfolio of over 70 companies.
Renegade Partners
Renegade Partners is an early-stage venture capital firm that partners with visionary founders, primarily in Series A rounds, across fintech and enterprise sectors. They offer hands-on support to help startups grow into enduring companies.
What's next for Auxilius?
The recent major strategic investment signifies Auxilius's transition into a scaling phase, likely focusing on expanding its market reach and enhancing its platform capabilities. With a strong foundation in automating complex financial processes for clinical trials, the company is well-positioned to capture a larger share of the biopharmaceutical financial technology market. Future strategic initiatives may include further integration with a broader range of healthcare IT systems, development of advanced AI-driven financial analytics, and expansion into new therapeutic areas or geographical markets. This latest backing will likely fuel product development and bolster sales and marketing efforts to solidify its position as a leader in clinical trial financial management.
See full Auxilius company page
